In this episode, Dr. Elizabeth Volkmann discusses emerging research on the gut microbiome in systemic sclerosis, building on findings from early-diagnosis and prior microbiome studies. She explains her team's analysis of microbiome-derived metabolites, including short-chain fatty acids, and their potential role in symptom development, highlighting key findings, clinical implications, and study limitations. The conversation also touches on holistic patient care, international collaboration, and her perspective on the future of systemic sclerosis research and treatment.

Characterization of the Fecal Metabolome in Patients With Early Systemic Sclerosis